Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. It has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.

Viatris Inc.

Last week, stocks pulled back from record highs as oil, yields, and rate fears returned to the forefront. The S&P 500 (SPX) ended at 7,408.50, down...

The Week That Was, The Week Ahead: Macro and Markets, May 17

Viatris ( ($VTRS) ) has provided an update. On May 15, 2026, Viatris Inc. held its 2026 annual meeting of shareholders, where investors voted on bo...

Viatris Shareholders Approve Directors, Pay and Auditor

In a report released today, Les Sulewski from Truist Financial reiterated a Buy rating on Viatris, with a price target of $20.00. According to TipR...

Current Quarter	$0.63	Next Quarter	$0.67
Current Year	$2.47	Next Year	$2.7
QoQ Growth	+6.3%	YoY Growth	+9.3%
3Y EPS CAGR	-100.0%	Target Price	$17.89
Consensus	Buy	Upside	+9.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	VTRS	$16.32	+0.39%	404.17K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	VTRS	$16.32	+0.4%	404.17K
3
4
5
6

VTRS

VTRS

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Viatris Inc. Data in Excel

Get Viatris Inc. Data in Excel